Quoin Pharmaceuticals Initiates Pediatric Trial of QRX003 for Netherton Syndrome
Key Insights
Quoin Pharmaceuticals has begun clinical testing of QRX003 in a pediatric patient with Netherton Syndrome (search) in Dublin.
The company plans to expand the trial to include three additional pediatric patients in Spain.
QRX003 is currently in late-stage clinical trials, showing promising results with no treatment-related adverse events.
Quoin Pharmaceuticals (NASDAQ: QNRX) has commenced clinical testing of QRX003 in a pediatric patient diagnosed with Netherton Syndrome (search) (NS) at Children's Health Ireland in Dublin, under the guidance of Dr. Alan Irvine. This marks the first evaluation of QRX003 in a pediatric population, with plans to extend the study to three additional pediatric patients in Spain.
QRX003 is currently undergoing evaluation in two late-stage clinical trials. Preliminary results have indicated improvements across multiple endpoints, with no treatment-related adverse events reported to date. These findings suggest a potentially favorable safety profile for the topical lotion.
Trial Expansion and Global Reach
In addition to the existing five clinical sites in the United States, Quoin Pharmaceuticals is broadening its clinical trial network. New sites are slated to open in Saudi Arabia and two in the United Kingdom, enhancing the geographical diversity of the study and potentially accelerating patient recruitment.
According to Dr. Michael Myers, CEO of Quoin, the expansion aims to generate a broad and diverse dataset for QRX003 in Netherton Syndrome (search) patients. The inclusion of pediatric patients and the collaboration with Professor Irvine, a leading researcher in the field, are expected to facilitate lowering the eligibility age for future trials.
About Netherton Syndrome and QRX003
Netherton Syndrome (search) is a rare, inherited skin disorder stemming from a mutation in the SPINK5 gene (search). This genetic defect leads to severe skin barrier defects, recurring infections, and a predisposition to allergies, asthma, and eczema. Patients often experience severe dehydration, chronic skin inflammation, and stunted growth. Currently, there is no cure for Netherton Syndrome, nor are there any approved therapeutic treatments available.
QRX003 is a topical lotion formulated with a proprietary delivery technology containing a broad-spectrum serine protease inhibitor. Its mechanism of action is designed to mimic the function of the LEKTI protein, which is deficient in Netherton Syndrome (search) patients. By promoting a more normalized skin-shedding process and strengthening the skin barrier, QRX003 aims to alleviate the symptoms and improve the quality of life for individuals with Netherton Syndrome.